Matrix metalloproteinases in bone development and pathology: current knowledge and potential clinical utility

Hai Po Helena Liang*
Joshua Xu*
Meilang Xue
Christopher J Jackson
Sutton Arthritis Research Laboratory, Institute of Bone and Joint Research, Kolling Institute, Sydney Medical School Northern, University of Sydney, St Leonards, NSW, Australia
*These authors contributed equally to this work

Abstract: Matrix metalloproteinases (MMPs) are degrading enzymes that have a pivotal function in extracellular matrix remodeling. More than half of the MMP members are expressed by bone and cartilage cells under physiological or pathological conditions such as rheumatoid arthritis, osteoarthritis, and osteoporosis. Through studies on the various bone diseases and on genetically modified mouse models in which one or more of the MMPs or their associated proteins and downstream signaling molecules have been targeted, it is becoming increasingly evident that MMPs and other players in their cellular pathway play a pivotal role in bone development and remodeling. This review details the latest findings related to MMPs and bone development and pathology.

Keywords: bone diseases, mouse models, gelatinases, collagenases, vascular endothelial growth factor, activated protein C, bone morphogenetic proteins, transforming growth factor

Introduction

There are two vital processes during bone development that are responsible for bone formation, intramembranous ossification and endochondral ossification. Intramembranous ossification is a process that forms most of the craniofacial skeleton through the direct differentiation of mesenchymal cells into bone. In contrast, endochondral ossification is a process of bone development in which cartilage is used as a template for bone morphogenesis. Endochondral ossification is responsible for the development of most of the bones including the long bones. In this process, mesenchymal cells undergo condensation and then differentiate into chondrocytes, which proliferate and undergo hypertrophy before dying. This leaves cavities for the invasion of blood vessels and bone-forming/bone-remodeling cells such as osteoclasts, osteoblasts, and bone marrow. Following this, ossification gradually occurs along the cartilage template to replace it with bone. Successful bone growth requires a mechanically stable cartilage model that can be degraded during ossification to allow for mineral deposition and ultimately bone formation.

The recruitment, survival, and function of osteoclasts and osteoblasts are essential for the prevention of metabolic bone diseases such as osteoporosis. In addition, these cells play an important role in promoting bone regeneration in pathological conditions such as rheumatoid arthritis (RA) and osteoarthritis (OA). RA and OA are characterized by synovitis, a destruction of the cartilage and the surrounding extracellular matrix (ECM). Remodeling of ECM in bones is therefore important for mediating bone development and repair. ECM remodeling in other areas including skin and blood...
vessels has also been indicated to mediate many different physiological and pathological processes, including wound healing and angiogenesis.6–9

Matrix metalloproteinases (MMPs) are a family of zinc-dependent ECM-degrading enzymes, which has been established to play a crucial role in ECM remodeling,10 and are the key enzymes responsible for cleaving structural components of the ECM such as collagen and gelatin, thereby enabling the ECM to degrade and regenerate.10 More than half of the MMP members are expressed in their active form by bone and cartilage cells under physiological and pathological conditions, and these MMPs are not only thought to have a pivotal involvement in bone and cartilage matrix degradation, but also important for osteoclast, osteoblast and osteocyte viability and functions, as well as chondrocyte proliferation and differentiation.8 This review provides an update on the role of MMPs in bone development and remodeling.

Overview of the classification, structure, expression, and regulation of MMPs
The 23 members of MMPs in humans (MMPs 1 through to 28, with MMP-4, MMP-5, MMP-6 and MMP-22 being removed from the classification due to duplication, and MMP-18 not found in humans) can be categorized into several different subtypes based on their structural and substrate affinity: collagenases (MMP-1, MMP-8 and MMP-13), gelatinases (MMP-2 and MMP-9), stromelysins (MMP-3, MMP-10 and MMP-11), matrilysins (MMP-7 and MMP26, membrane-type metalloproteinase (MMP-14, MMP-15, MMP-16, MMP-17 and MMP-24), and others (MMP-12, MMP-19, MMP-20, MMP-21, MMP-23, MMP-25, MMP-27 and MMP-28). Each member of these MMPs is encoded by a different gene, except for MMP-23, which is encoded by two identical genes (MMP-23A and MMP-23B) on chromosome 1.11 All MMPs share three common structures: the predomain (PRE) for protein secretion, the prodomain (PRO) responsible for the regulation of protein function, and the zinc-dependent catalytic endopeptidase motif,12 which are necessary for substrate processing. MMPs are expressed as inactive proenzymes that can be activated by the proteolytic cleavage of the propeptide to reveal its active site. The cleavage of the propeptide and activation of all MMPs, with the exception MMP-23, is thought to be mediated by a cysteine amino acid in the molecule’s prodomain, via extracellular proteinases and other MMPs, in a process called “cysteine switching”.13 The regulation of MMP expression and activity occurs at multiple levels, including gene transcription,14 translation and secretion of the inactive proenzyme,15 and proenzyme activation and inactivation via signaling from cytokines, growth factors, integrins, and ECM proteins.13,16 Examples of classic MMP activators include the activator protein-1, nuclear factor kappa B, tumor necrosis factor-alpha, transforming growth factor beta (TGFβ), as well as certain interleukins. The main inhibitors of MMPs are the tissue inhibitors of MMPs (TIMPs) secreted by the ECM.17

Roles of MMPs and TIMPs during bone development, remodeling, and repair
Currently, the most abundantly expressed and functionally important MMPs in bone and cartilage cells during normal skeletal development are identified to be MMP-2 (also known as gelatinase A), MMP-9 (gelatinase B), MMP-13 (collagenase 3), MMP-14 (membrane-type 1 MMP), and MMP-16 (membrane-type 3), based on in vivo studies using MMP gene knockout mice and preclinical experimental arthritis models, as well as investigations of human genetic diseases involving MMP gene mutations.8 The roles of each of these MMPs and TIMPs are discussed as follows.

MMP-2
MMP-2, also known as gelatinase A, is a 72 kDa gelatinase that can cleave type I, IV, V, VII, and XI collagens along with aggrecans, gelatins, fibronectin, laminin, large tenascin-C, and elastin.18 Inactivating mutations of the human gene expressing MMP-2 were first identified in patients with inherited multicentric osteolysis and arthritis or the “vanishing bone” syndrome. This autosomal recessive condition was first reported in large Saudi Arabian families in which intermamial marriage had occurred.19,20 The patients suffered from severe arthropathy, osteoporosis, and subcutaneous nodules with distinctive craniofacial defects that included exophthalmos, brachycephaly, and flattened nasal bridges.21 Children with multicentric osteolysis and arthritis exhibit normal birth weight but stunted growth rates in terms of both height and weight.21 By examining the population suffering from these distinctive bone phenotypes, the disease gene was identified at 16q12-21, a region encoding the expression of MMP-2.22

MMP-2 knockout mice have been used to elucidate the function of MMP-2 on bone. MMP-2 knockout mice, when compared to wild-type mice, were initially shown to have almost completely normal early development, with only a slight delay in bone development and were smaller in size at birth.23 However, further studies found that the long bones of MMP-2 knockout mice had osteopenia with the tibiae of many of these mice spontaneously becoming fractured.24 It is
postulated that the reduced bone integrity in MMP-2 knockout mice is caused by disruptions to the osteocytic canalicular networks in bone. The canalicular spaces are locations in which mineral ion exchanges occur during the resorption and mineralization of the bone matrix. Thus, disruption to these canalicular networks could possibly inhibit the mineralization and hardening of bone. An increase in MMP-2 protein expression has also been detected in fracture callus, and bone mineralization may be one aspect by which MMP-2 mediates bone remodeling during fracture repair. Nyman et al support this postulation as they found that the ratio of mineral to collagen is decreased in the bone of MMP-2 knockout mice. Along with the reduced bone mineralization density, the diaphysis cortex in the tibia of MMP-2 knockout mice is 23% thinner than the wild type. MMP-2 deficiency has also been shown to reduce tibia and femur length in adult mice. Histological analysis also revealed less dense and very disordered trabeculae. Since the osteocytic canalicular networks of MMP-2 knockout mice are repaired following transplantation of wild-type periosteum, MMP-2 may mediate its effects on bone via a local mechanism. Thus, MMP-2 appears to play a role in maintaining bone mineral density and strength, possibly via its local action on the ECM to produce canalicular networks.

The craniofacial defects observed in MMP-2 knockout mice are also comparable to those seen in humans with multicentric osteolysis and arthritis as a result of the inactivating mutation to the MMP-2 gene. The knockout mice have shorter, broader snouts along with hypertelorism and smaller jaws. It has been postulated that MMP-2 acts via type I collagen, as its inhibition of type I collagen cleavage caused similar craniofacial defects in mice as MMP-2 knockout. There is also abnormal bone development of the calvaria, which is the only bone reported to undergo sclerosis with increased bone deposition and osteocyte loss which is likely due to the increased osteoblastic activity in the calvarie. No changes in blastocyst activity have been detected in the long bones of MMP-2 knockout mice. These findings are interesting as ex vivo studies have shown poor proliferation of osteoblasts with MMP-2 knockout calvarial bone marrow stromal cells. In agreement, targeted siRNA-mediated MMP-2 knockout decreases osteoblast proliferation ex vivo. The different findings in vivo and ex vivo can possibly be explained by the fact that MMP-2 knockout in mice can directly induce the expression of osteopontin and bone sialoprotein. While osteopontin has been shown to mediate an increase in osteoclast activity, bone sialoprotein can enhance osteoblast differentiation and activity. Thus, the varying expression of these two proteins in different bones can account for either increased bone reabsorption or bone growth. Ultimately, there is evidence that MMP-2 affects bone development via its effect on osteoclast and osteoblast activity and proliferation; however, the mechanisms are still not fully elucidated.

**MMP-9**

MMP-9, also known as gelatinase B, is a 92 kDa collagenase that has high specific degradative activity for denatured collagens in the ECM. It can cleave elastin and native type IV, V, and XI collagens, but not non-native type I collagen, proteoglycan, or laminins. MMP-9 is also able to cleave non-ECM molecules such as substance P, amyloid beta peptide, and myelin basic protein. The expression of MMP-9 varies through the stages of development. In early development, MMP-9 is expressed in trophoblasts and osteoclasts, suggesting that it plays a role in implantation and bone resorption. With maturity, MMP-9 is primarily expressed in inflammatory cells during diseases such as RA and cancer.

There are numerous postulated methods by which MMP-9 can influence bone development and strength. Long bones in MMP-9 knockout mice are 10% shorter than those of the wild-type mice. These knockout mice also demonstrate an accumulation of lengthened hypertrophic chondrocytes at the growth plate, despite normal proliferation of these cells. It has been postulated that MMP-9 is required for the cleavage of galectin-3 to prevent accumulation of late hypertrophic chondrocytes. These findings suggest that MMP-9 plays a role in influencing the structural properties of whole bones through its activity at the growth plate during endochondral bone formation. This is supported by evidence that MMP-9 null mice have delayed skeletal growth plate vascularization and ossification of hypertrophic cartilage which is confined to just the growth plate cartilage. Bone marrow transplantation of MMP-9 null mice corrects all bone growth defects, suggesting that the critical cells expressing MMP-9 are of bone marrow origin. Interestingly, the MMP-9 null mice do not have any issues with implantation or development into fertile adults, suggesting that alternate physiological processes can compensate for some roles of MMP-9.

MMP-9 can also influence the bending strength and toughness of bone. MMP-9 knockout mice have improved connectivity density of the tibia trabeculae at the metaphysis with no overall volume changes. Yield strength, defined as the force required before plastic deformation, was slightly higher in the MMP-9 knockout mice when compared with the wild types. Interestingly, however, the bones of MMP-9...
knockout mice were more brittle. Although the mechanisms are not fully known, it is postulated that MMP-9 may affect ECM proteins such as type I collagen to alter ECM organization and thereby influence bone strength and brittleness. Recently, MMP-9 has been reported to also be necessary for the regulation of gene pathways that are required for osteoclastogenesis, through its proteolytic interaction with the histone H3 N-terminal tail (H3NT). Further studies must be conducted to better understand the mechanisms underlying these bone pathologies in MMP-9 null mice.

MMP-13
Cartilage consists of chondrocytes and a large amount of ECM, which is made up of proteoglycans, aggrecans, and collagens, mainly type II. Type II collagen is extremely resistant to degradation by most proteinases because of its triple-helical structure. Only the classical collagenases including MMP-1, MMP-8, and MMP-13, and to a much less extent, MMP-14, are able to degrade type II collagen fibrils and denature them into gelatin, which can then be subsequently digested into small peptides by the gelatinases. Due to its preferential digestion of type II collagen over other collagen types, MMP-13, which is derived from chondrocytes, synovial cells, and osteoblasts, is considered to be the most important collagenase for the degradation of cartilage.

The proenzyme form of MMP-13 is ~60 kDa in size and can be activated by MMP-2, MMP-3, MMP-14, and plasmin. The expression and type II collagen degradation activity of the 48 kDa active MMP-13 can also be upregulated by ECM proteins such as type X collagen and periostin. There is now mounting evidence to suggest that increased MMP-13 activity is associated with articular cartilage degeneration and joint pathology typical of OA in animal models, and that MMP-13 expression is critical for OA disease progression. Therefore, the development of pharmacologic inhibitors of MMP-13 in recent years seems to be an effective strategy to modify OA disease outcome. In addition, a MMP-13 activity probe seems to be useful for in vivo imaging in OA disease diagnosis and differentiating disease severity. MMP-13-deficient mice also show significantly decreased disease severity in the antibody-induced arthritis model, thus implicating the important role of MMP-13 as a regulator of inflammation and revealing it as a potential therapeutic target for inflammatory arthritis.

MMP-13 knockout mice exhibit a normal lifespan and are fertile, with no gross phenotypic abnormalities. However, these mice have demonstrated marked defects in their growth plate cartilage, with a significant increase in the hypertrophic chondrocyte zones but normal chondrocyte proliferation, and a delay in endochondral ossification, particularly at the secondary ossification center. The mice also show increased trabecular bone mass but irregular bone spicules. This subsequently results in impairment of bone matrix organization and cartilage ECM remodeling in these animals, which leads to a reduction in both toughness and fracture resistance of their long bones, but ultimately the mice show no notable abnormalities in their long bone development.

MMP-13 is a downstream target of the transcription factor Cbfa1/Runx2 in hypertrophic chondrocytes, as Cbfa1 knockout mice fail to express MMP-13 during fetal development. C-maf deficiency, on the other hand, markedly suppresses collagen degradation by MMP-13, thereby resulting in abnormal terminal differentiation of chondrocytes which leads to prolongation of the chondrocyte hypertrophic state. Hence, MMP-13 has been implicated in the initiation of bone resorption.

MMP-9 and MMP-13 double knockout mice have exacerbated phenotypes compared to MMP-9 or MMP-13 single-knockout mice, including disorganized architecture of the hypertrophic chondrocyte zone and increased number of terminally differentiated hypertrophic chondrocytes. In contrast to MMP-13 single-knockout mice but similar to MMP-9 single-knockout mice, the double knockouts show a reduction of trabecular bone formation at the growth plate. Interestingly, there is no abnormality in aggrecan degradation in the MMP-9 and MMP-13 double knockouts, despite the absence of the aggrecan cleavage product in these mice, suggesting that other mechanisms exist for the removal of aggrecan during cartilage to bone transitions. This is consistent with a subsequent study on an aggrecan knock-in mouse strain that is resistant to cleavage by all MMPs in the aggrecan proteinase-sensitive interglobular domain.

In humans, missense mutations in MMP-13 cause a genetic bone disorder called spondyloepimetaphyseal dysplasia characterized by defective growth and abnormal modeling of the spine and long bones in childhood, which spontaneously resolves by adolescence. These transient disease phenotypes appear to be caused by the late exit of chondrocytes from the growth plate, despite normal differentiation, consistent with the findings from knockout mice models. Further studies on the role of MMP-13 in bone remodeling in experimental arthritis mice models will likely provide better insights into the pathological process of such human bone disorders.
**MMP-14**

MMP-14 is a membrane-bound protein that is expressed highly by periskeletal and skeletal tissue. MMP-14 knockout mice have a very high mortality, with 33% of these dying due to wasting before they are weaned, and at 50–90 days nearly all these mutant mice die due to wasting. MMP-14 knockout mice also display abnormal cranial bone formation, short snouts, hypertelorism, and dome-shaped skulls along with growth impairment with respect to both weight and body size. MMP-2 and MMP-14 double knockout mice also die immediately after birth, and there may be some functional overlap between these two MMPs, as the cranial defects in MMP-14 deficiency are very similar to those seen in MMP-2-deficient mice. It has been postulated that the MMP-14 knockout mouse inhibits fibroblast growth factor signaling, which is believed to be essential in intramembranous ossification of cranial bones. In addition, MMP-14 null mice show decreased MMP-2 activity, as expected since MMP-14 is the major activator of MMP-2.

The bone mass of MMP-14 knockout mice is greatly reduced, with joints displaying articular cartilage loss. This is due to the greater bone resorption and reduced bone formation in MMP-14 knockout mice. MMP-14 knockout mice elicit these effects via intrinsic deficits to the osteogenic cells as opposed to other systemic causes. By culture-expanding populations of marrow-derived osteogenic cells from MMP-14 mice, it was found that these cells in particular display impaired osteogenic capacity and collagen-degrading activity. This may be mediated by the reduced ability for MMP-14 knockout animals to release CD44 from the cell membrane, as CD44 is important in osteocyte cell–cell signaling with its knockout producing shortened long bones and reduced osteoclast activity. MMP-14 may also interact with transduction signaling cascades, with a novel function of MMP-14 being its mechano-sensory role in osteocytes.

While the calcification of metaphyseal growth plates at birth is normal in MMP-14-deficient mice, there are significant delays in secondary epiphyseal ossification. In addition, vascularization of the epiphyseal growth cartilage does not occur, which is a finding comparable to that of MMP-9 knockout mice. Reconstituted MMP-14 activity has been shown to act on type II collagen-expressing cells to ameliorate skeletal dysplasia and rescue chondrocyte proliferation. Overall, it is believed that MMP-14 deficiency compromises apoptosis of chondrocytes and cartilage breakdown, preventing normal endochondral ossification. Thus, MMP-14 plays an important role in bone development and growth.

**MMP-16**

MMP-16 present in osteoblasts and osteocytes acts by breaking down ECM proteins such as high-density fibrillar type I collagen, thus promoting bone growth and development. The mechanism of ECM degradation via MMP-16 is necessary for the proper functioning of mesenchymal cells expressed on skeletal tissue. In fact, mice lacking MMP-16 demonstrate stunted growth due to the decreased viability of these mesenchymal cells. MMP-16 has been examined along with MMP-14, as both enzymes have similar molecular structures and tissue expression patterns. In the double knockout of MMP-14 and MMP-16, the mortality was even higher than that of MMP-14 alone as described earlier, with the majority dying within the first day of birth due to developmental abnormalities. In contrast, the single knockout of MMP-16 did not result in any premature deaths. This suggests that MMP-16 is not essential for post-embryonic bone development in mice, unlike MMP-14. Furthermore, the double knockout of MMP-14 and MMP-16 led to even more pronounced craniofacial deformities and cortical bone shortening than that observed in the single deficiencies. The loss of both the MMPs also elicited greater nuclei apoptosis in the bone-lining cells along with reduced chondrocyte proliferation and cartilage remodeling, when compared to single knockout of the MMP-14 gene. These observations not only are tied to the loss of bone collagenolytic activity, but also imply that MMP-16 can partly compensate for the action of MMP-14.

**TIMPs**

TIMP-1 and TIMP-2 are the most studied natural inhibitors of the MMPs and the most highly expressed during bone development. TIMP-1 is expressed in chondrocytes of all zones in the growth plate, as well as in osteoblasts, osteocytes, and osteoclasts. Mice overexpressing TIMP-1 in osteoblasts were found by Geoffroy et al to have increased trabecular bone volume and decreased bone turnover, hence indicative of an important regulatory role in bone formation and remodeling that is likely to be dependent on its MMP inhibitory activity. TIMP-2 has also been found to be expressed by hypertrophic chondrocytes and osteoblasts, and both TIMP-1 and TIMP-2 are able to directly stimulate the bone-resorbing activity of osteoclasts in vitro at physiological concentrations, and this is likely to be independent of their inhibition of MMPs. Other TIMP members including TIMP-3 and TIMP-4 are also expressed in bone and joint tissues, and an increased expression of these have been associated with OA.
Metalloproteinases In Medicine downloaded from https://www.dovepress.com/ by 54.70.40.11 on 17-Jun-2019
For personal use only.
Powered by TCPDF (www.tcpdf.org)

Liang et al

Metalloproteinases In Medicine 2016:3

Interactions of MMPs with other proteins in bone development, remodeling, and repair

Other proteins that interact with the aforementioned MMPs in bone development and disease are briefly described as follows and are summarized in Table 1.

TGF\(\beta\)

The actions of MMPs on bone turnover and remodeling can be exerted via their interaction with various other proteins. Both MMP-2 and MMP-9 can regulate the bioavailability and bioactivity of TGF\(\beta\), a molecule that affects the mechanical properties and composition of bone matrix.\(^\text{27,84,85}\) When TGF\(\beta\) signaling is increased in mice, the modulus and hardness of their bones decrease.\(^\text{85}\) In addition, MMP-14 expressed by osteoblasts has also been reported to have the ability to activate TGF\(\beta\), thereby maintaining the survival of osteoblasts upon completion of bone matrix synthesis during bone remodeling and driving them to differentiate into osteocytes.\(^\text{86}\) Conversely, TGF\(\beta\) is able to significantly upregulate MMP-13 expression in osteoblasts, thereby inducing changes in osteoblast morphology that in turn promotes osteoclastic bone resorption.\(^\text{87}\)

Bone morphogenetic proteins

Bone morphogenetic proteins (BMPs) are multifunctional secreted growth factors that also belong to the TGF\(\beta\) superfamily.\(^\text{88}\) Conditional and tissue-specific knockout mouse models provide strong evidence on the pivotal roles of BMPs, as well as their receptors and effectors, in bone formation and resorption.\(^\text{88–90}\) Inhibition of the BMP receptor and its downstream signaling by a pharmacological ligand significantly reduces the expression and activity of both MMP-2 and MMP-9, thereby obstructing tissue regeneration and remodeling in teleost fish \textit{Poecilia latipinna} following amputation.\(^\text{91}\) Similarly in mice with BMP type IA receptor (BMPRIA) deficiency specifically in osteoblasts, MMP-9 expressed by osteoclasts was significantly reduced, impairing bone resorption and finally resulting in increased bone mass during early development.\(^\text{90}\) Additionally, Choi et al\(^\text{92}\) reported that downregulation of MMP-9 activity promotes

### Table 1 Proteins that interact with MMPs and TIMPs in bone development and disease

<table>
<thead>
<tr>
<th>Protein</th>
<th>Interacting MMPs</th>
<th>Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>TGF(\beta)</td>
<td>MMP-2</td>
<td>MMP-2 regulates the bioavailability and bioactivity of TGF(\beta), thereby affecting bone hardness and bone matrix composition(^\text{7,84,85})</td>
</tr>
<tr>
<td></td>
<td>MMP-9</td>
<td>MMP-9 regulates the bioavailability and bioactivity of TGF(\beta), thereby affecting bone hardness and bone matrix composition(^\text{7,84,85})</td>
</tr>
<tr>
<td></td>
<td>MMP-13</td>
<td>MMP-13 is upregulated by TGF(\beta), which induces changes in osteoblast morphology and promotes bone resorption(^\text{87})</td>
</tr>
<tr>
<td></td>
<td>MMP-14</td>
<td>MMP-14 activates TGF(\beta), which helps to regulate osteoblast differentiation and survival(^\text{96})</td>
</tr>
<tr>
<td>BMP</td>
<td>MMP-2</td>
<td>MMP-2 is regulated by BMP, thereby affecting tissue regeneration and remodeling(^\text{81})</td>
</tr>
<tr>
<td></td>
<td>MMP-9</td>
<td>MMP-9 is regulated by BMP, thereby affecting bone resorption and remodeling, as well as chondrocyte commitment(^\text{90–95})</td>
</tr>
<tr>
<td>Wnt/(\beta)-catenin</td>
<td>MMP-2</td>
<td>MMP-2 is regulated by Wnt/(\beta)-catenin signaling, thereby modulating chondrocyte function and affecting growth plate organization, cartilage formation, and endochondral ossification during bone development(^\text{95})</td>
</tr>
<tr>
<td></td>
<td>MMP-9</td>
<td>MMP-9 is upregulated by Wnt/(\beta)-catenin signaling, thereby modulating bone resorption and cartilage degradation(^\text{90,102,105})</td>
</tr>
<tr>
<td></td>
<td>MMP-13</td>
<td>MMP-13 is upregulated by Wnt/(\beta)-catenin signaling, thereby modulating vascularization of cartilage during development, bone formation, and remodeling(^\text{102–105})</td>
</tr>
<tr>
<td>VEGF</td>
<td>MMP-9</td>
<td>MMP-9 regulates the bioavailability and bioactivity of VEGF, thereby affecting osteoclast recruitment during bone resorption(^\text{108–110})</td>
</tr>
<tr>
<td>aPC</td>
<td>MMP-2</td>
<td>MMP-2 activity is upregulated by aPC in RA patients, thereby suppressing pro-inflammatory signaling as well as bone and cartilage degradation in RA patients(^\text{116–118})</td>
</tr>
<tr>
<td></td>
<td>MMP-9</td>
<td>MMP-9 activity is downregulated by aPC in synovial fibroblasts, thereby suppressing pro-inflammatory signaling as well as bone and cartilage degradation in RA patients(^\text{117,119})</td>
</tr>
<tr>
<td>TIMPs</td>
<td>All MMPs</td>
<td>MMP inhibitors that can regulate osteocytic differentiation, bone formation, resorption, and remodeling(^\text{1,76–83})</td>
</tr>
</tbody>
</table>

Abbreviations: aPC, activated protein C; BMP, bone morphogenetic protein; MMP, matrix metalloproteinase; RA, rheumatoid arthritis; TGF\(\beta\), transforming growth factor-beta; TIMP, tissue inhibitor of MMPs; VEGF, vascular endothelial growth factor.
BMP-2-induced chondrocyte commitment of the mouse C3H10T1/2 stem cell line via modulation of glycogen synthase kinase-3β signaling.

**Wnt/beta-catenin**

Wnt proteins are a large glycoprotein family that play important roles in various development and cell renewal processes.93,94 and there is increasing evidence that suggests that the canonical Wnt/β-catenin signaling pathway may be involved in cartilage destruction in RA and OA.94–96 Various research groups have reported that the expressions of several Wnt proteins, as well as the expressions of Wnt inhibitors known as the frizzled-related proteins, were altered in the synovium and cartilage of RA and OA patients compared to normal controls.97–99 BMP-induced Wnt/β-catenin signaling was demonstrated to regulate the expressions of TGFβ, MMP-2, MMP-9, MMP-13, and TIMP-1 in various bone cells including osteoblasts, osteoclasts, and articular chondrocytes,90,100–105 which can ultimately regulate bone and cartilage formation, development, and remodeling, and hence have important implications in bone disease progression.

**Vascular endothelial growth factor**

Vascular endothelial growth factor (VEGF), an important angiogenic factor that acts mainly on endothelial cells, but also stimulates osteoblasts and OA chondrocytes,106,107 has been implicated to regulate endochondral ossification and bone formation.108 The bioavailability and activity of VEGF is believed to be at least partially regulated by MMP-9.108,109 In addition, MMP-9 has been suggested to specifically regulate the ECM-bound VEGF, exerting direct chemotactic activity on osteoclasts, thereby affecting their recruitment during bone resorption.110

**Activated protein C**

Activated protein C (aPC) is best known for its anticoagulant activity. However, it also has potent ability to promote growth and dampen inflammation.111–114 aPC increases osteoblast viability and signaling, promotes recombinant human recombinant BMP-2-induced ectopic bone formation, and enhances angiogenesis in vivo in a protease-activated receptor-1-dependent manner,115 suggesting that aPC may have the potential to be used in conjunction with rhBMP-2 as a therapeutic for bone repair.115 aPC was first reported to play a role in regulating MMP activity by Nguyen et al116 who showed that aPC directly activates MMP-2 in human umbilical vein endothelial cells. In RA, aPC co-localizes with and selectively upregulates and activates MMP-2, while at the same time inhibiting MMP-9 in synovial fibroblasts and monocytes, resulting in suppressing of the pro-inflammatory signaling in RA patients.117,118 This is explained by the finding that endogenous MMP-9 but not MMP-2 promotes rheumatoid synovial fibroblast survival, inflammation, and cartilage degradation resulting in potential bone loss.119

**Conclusion**

In summary, bone is a highly dynamic and continuously remodeling tissue during development, homeostasis, and tissue repair. Half of the MMP members have been detected in bone tissue during development and in pathological conditions involving bone degradation. Knockout mouse models have confirmed the crucial functions of MMPs during bone development and regeneration. MMPs and proteins that modulate or are modulated by MMPs are potential targets for improving bone tissue repair. Better understanding of the regulatory mechanisms of MMPs and further elucidation of their cellular pathways in ECM remodeling is necessary for future therapeutic development.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


